Biocept, Inc.
BIOC · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | -$10 | $6 |
| % Growth | -12.5% | 106.5% | -284.1% | – |
| Cost of Goods Sold | $3 | $3 | $4 | $6 |
| Gross Profit | -$2 | -$2 | -$15 | -$0 |
| % Margin | -332.9% | -349.9% | 141.9% | -3.4% |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $3 | $3 | $2 | $3 |
| SG&A Expenses | $4 | $4 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $4 | $5 |
| Operating Income | -$6 | -$7 | -$19 | -$6 |
| % Margin | -1,038% | -1,054.7% | 180.9% | -99.8% |
| Other Income/Exp. Net | $2 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$4 | -$7 | -$19 | -$6 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$4 | -$7 | -$19 | -$6 |
| % Margin | -616.5% | -1,075.2% | 180.1% | -98.7% |
| EPS | -3,503.04 | -12.46 | -32.58 | -9.8 |
| % Growth | -28,014.3% | 61.8% | -232.4% | – |
| EPS Diluted | -3,503.04 | -12.32 | -32.57 | -9.73 |
| Weighted Avg Shares Out | 0 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$3 | -$6 | -$18 | -$5 |
| % Margin | -545.2% | -963.4% | 176.6% | -91% |